Ohio State University Comprehensive Cancer Center
Clinical Trials
338
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (295 trials with phase data)• Click on a phase to view related trials
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
- Conditions
- Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer
- Interventions
- Drug: Neoadjuvant ChemotherapyRadiation: Radiation TherapyProcedure: MRIProcedure: BiopsyProcedure: Breast Cancer SurgeryProcedure: Biospecimen collection
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Target Recruit Count
- 84
- Registration Number
- NCT07217990
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
- Conditions
- Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Locally Advanced Basal Cell CarcinomaLocally Advanced Malignant Skin NeoplasmLocally Advanced Merkel Cell CarcinomaLocally Advanced Mucosal MelanomaLocally Advanced Squamous Cell Carcinoma
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Target Recruit Count
- 70
- Registration Number
- NCT07215988
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants
- Conditions
- Hematopoietic and Lymphatic System NeoplasmPsychiatric DisorderMalignant Solid Neoplasm
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Target Recruit Count
- 32
- Registration Number
- NCT07216534
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Examining Heavy Metal Exposure and Respiratory Health in Young Adult Electronic Cigarette Users
- Conditions
- Heavy Metal Exposure From Vaping
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Target Recruit Count
- 100
- Registration Number
- NCT07215065
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Strategies for Optimizing a Mailed FIT Program in Appalachia
- Conditions
- Colonic Neoplasms
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-19
- Target Recruit Count
- 500
- Registration Number
- NCT07173985
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 68
- Next
News
FDA Grants Fast Track Designation to NG-350A for Mismatch Repair-Proficient Locally Advanced Rectal Cancer
The FDA has granted fast track designation to NG-350A, an oncolytic immunotherapy developed by Akamis Bio, for treating mismatch repair-proficient locally advanced rectal cancer.
TAE Life Sciences and Ohio State University Partner to Advance Boron Neutron Capture Therapy for Cancer Treatment
TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).
ACCC Fall 2024: Innovations in Clinical Trial Access, Patient Care, and Treatment Authorization
The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.
First-in-Human Trial Launched for Novel DHODH Inhibitor HOSU-53 in Solid Tumors and Lymphomas
A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma.
Nanopharmaceutics Completes Enrollment in Phase 2 Neuroendocrine Tumor Study Combining Triapine with Lutetium Lu 177 Dotatate
Nanopharmaceutics has completed patient enrollment in a 94-patient Phase 2 randomized controlled trial evaluating Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.